NASDAQ:PTCT - PTC Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$31.99 +0.45 (+1.43 %)
(As of 05/20/2018 03:38 PM ET)
Previous Close$31.99
Today's Range$31.33 - $32.58
52-Week Range$12.15 - $33.22
Volume966,075 shs
Average Volume867,530 shs
Market Capitalization$1.49 billion
P/E Ratio-15.84
Dividend YieldN/A
Beta1.66

About PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics logoPTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy. It is developing Translarna, which is in Phase II clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 for the treatment of patients with spinal muscular atrophy, as well as PTC596, an orally bioavailable and potent small molecule that has completed Phase I study, which targets solid tumor cell populations by reducing the activity and amount of BMI1. The company has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and research collaboration with CHDI Foundation, Inc. to discover and develop small-molecule therapeutics for Huntington's disease. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Receive PTCT News and Ratings via Email

Sign-up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PTCT
CUSIPN/A
Phone908-222-7000

Debt

Debt-to-Equity Ratio0.98
Current Ratio3.33
Quick Ratio3.16

Price-To-Earnings

Trailing P/E Ratio-15.84
Forward P/E Ratio-20.64
P/E GrowthN/A

Sales & Book Value

Annual Sales$194.39 million
Price / Sales7.64
Cash FlowN/A
Price / CashN/A
Book Value$3.24 per share
Price / Book9.87

Profitability

EPS (Most Recent Fiscal Year)($2.02)
Net Income$-79,000,000.00
Net Margins-30.91%
Return on Equity-40.42%
Return on Assets-16.53%

Miscellaneous

Employees373
Outstanding Shares46,450,000

PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions

What is PTC Therapeutics' stock symbol?

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics (NASDAQ:PTCT) announced its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by $0.03. The biopharmaceutical company had revenue of $56.10 million for the quarter, compared to analyst estimates of $63.46 million. PTC Therapeutics had a negative net margin of 30.91% and a negative return on equity of 40.42%. PTC Therapeutics's revenue was up 111.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.85) earnings per share. View PTC Therapeutics' Earnings History.

When is PTC Therapeutics' next earnings date?

PTC Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for PTC Therapeutics.

What price target have analysts set for PTCT?

8 analysts have issued 12 month price objectives for PTC Therapeutics' shares. Their predictions range from $15.00 to $35.00. On average, they expect PTC Therapeutics' stock price to reach $22.6667 in the next twelve months. View Analyst Ratings for PTC Therapeutics.

What are Wall Street analysts saying about PTC Therapeutics stock?

Here are some recent quotes from research analysts about PTC Therapeutics stock:
  • 1. William Blair analysts commented, "CX-072 Data at ASCO. CTMX’s lead proprietary program, CX-072, will have first in human data at ASCO, both monotherapy (A") arm and combination with ipilimumab (B") arm. Since these data are early and not complete data sets, high levels of response rates may not be likely, but we think activity, even a modest level, could represent upside for the shares given that this is first in human data. We think a key proof of the technology will be measurement of systemically active versus intact" Probody CX-072." (5/10/2018)
  • 2. According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (5/9/2018)
  • 3. Cowen Inc analysts commented, "Yesterday Clearside announced the completion of enrollment in the TYBEE study in." (10/25/2017)

Are investors shorting PTC Therapeutics?

PTC Therapeutics saw a decrease in short interest in April. As of April 13th, there was short interest totalling 4,260,918 shares, a decrease of 22.8% from the March 30th total of 5,521,035 shares. Based on an average daily volume of 873,026 shares, the days-to-cover ratio is presently 4.9 days. Currently, 10.8% of the shares of the company are sold short.

Who are some of PTC Therapeutics' key competitors?

Who are PTC Therapeutics' key executives?

PTC Therapeutics' management team includes the folowing people:
  • Dr. Stuart W Peltz, Co-Founder, CEO & Exec. Director (Age 58)
  • Dr. Allan Steven Jacobson, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 72)
  • Dr. Neil Almstead Ph.D., Exec. VP of Research, Pharmaceutical Operations & Technology (Age 51)
  • Mr. Mark Elliott Boulding, Chief Legal Officer, EVP & Sec. (Age 57)
  • Ms. Christine Utter, Principal Financial & Accounting Officer and Treasurer

Has PTC Therapeutics been receiving favorable news coverage?

News coverage about PTCT stock has been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. PTC Therapeutics earned a news impact score of 0.18 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.27 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Scopia Capital Management LP (12.73%), BlackRock Inc. (7.07%), Millennium Management LLC (1.46%), Northern Trust Corp (1.43%), Spark Investment Management LLC (1.41%) and Frontier Capital Management Co. LLC (1.40%). Company insiders that own PTC Therapeutics stock include Christine Marie Utter, Dawn Svoronos, Neil Gregory Almstead and Stuart Walter Peltz. View Institutional Ownership Trends for PTC Therapeutics.

Which institutional investors are selling PTC Therapeutics stock?

PTCT stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Dimensional Fund Advisors LP, Asymmetry Capital Management L.P., American Century Companies Inc., UBS Group AG, South Dakota Investment Council, Guggenheim Capital LLC and Pinnacle Associates Ltd.. Company insiders that have sold PTC Therapeutics company stock in the last year include Christine Marie Utter, Neil Gregory Almstead and Stuart Walter Peltz. View Insider Buying and Selling for PTC Therapeutics.

Which institutional investors are buying PTC Therapeutics stock?

PTCT stock was acquired by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Frontier Capital Management Co. LLC, BlackRock Inc., Opaleye Management Inc., Millennium Management LLC, Candriam Luxembourg S.C.A., Schwab Charles Investment Management Inc. and Federated Investors Inc. PA. View Insider Buying and Selling for PTC Therapeutics.

How do I buy shares of PTC Therapeutics?

Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PTC Therapeutics' stock price today?

One share of PTCT stock can currently be purchased for approximately $31.99.

How big of a company is PTC Therapeutics?

PTC Therapeutics has a market capitalization of $1.49 billion and generates $194.39 million in revenue each year. The biopharmaceutical company earns $-79,000,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. PTC Therapeutics employs 373 workers across the globe.

How can I contact PTC Therapeutics?

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]


MarketBeat Community Rating for PTC Therapeutics (PTCT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  339 (Vote Outperform)
Underperform Votes:  324 (Vote Underperform)
Total Votes:  663
MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe PTCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTCT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

PTC Therapeutics (NASDAQ:PTCT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for PTC Therapeutics in the last 12 months. Their average twelve-month price target is $22.6667, suggesting that the stock has a possible downside of 29.14%. The high price target for PTCT is $35.00 and the low price target for PTCT is $15.00. There are currently 2 sell ratings, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.132.11
Ratings Breakdown: 2 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.6667$22.6667$19.6667$18.1429
Price Target Upside: 29.14% downside13.22% downside27.24% downside19.83% upside

PTC Therapeutics (NASDAQ:PTCT) Consensus Price Target History

Price Target History for PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics (NASDAQ:PTCT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018William BlairReiterated RatingHoldHighView Rating Details
4/3/2018BarclaysDowngradeEqual Weight ➝ Underweight$24.00 ➝ $26.00HighView Rating Details
2/21/2018CitigroupBoost Price TargetBuy ➝ Buy$24.00 ➝ $35.00HighView Rating Details
1/30/2018Credit Suisse GroupReiterated RatingBuy$28.00MediumView Rating Details
1/29/2018Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector PerformHighView Rating Details
11/24/2017JPMorgan ChaseBoost Price TargetUnderweight ➝ Neutral$15.00N/AView Rating Details
10/26/2017Bank of AmericaDowngradeNeutral ➝ UnderperformN/AView Rating Details
10/25/2017CowenReiterated RatingHoldN/AView Rating Details
1/10/2017Jefferies GroupReiterated RatingHold$12.00N/AView Rating Details
11/11/2016WedbushReiterated RatingNeutral$12.00 ➝ $7.00N/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

PTC Therapeutics (NASDAQ:PTCT) Earnings History and Estimates Chart

Earnings by Quarter for PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics (NASDAQ:PTCT) Earnings Estimates

2018 EPS Consensus Estimate: ($0.64)
2019 EPS Consensus Estimate: $1.29
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.61)($0.61)($0.61)
Q2 20181$0.03$0.03$0.03
Q3 20181($0.31)($0.31)($0.31)
Q4 20181$0.25$0.25$0.25
Q1 20191$0.21$0.21$0.21
Q2 20191$0.22$0.22$0.22
Q3 20191$0.65$0.65$0.65
Q4 20191$0.21$0.21$0.21

PTC Therapeutics (NASDAQ PTCT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.24)N/AView Earnings Details
5/9/2018Q1 2018($0.43)($0.46)$63.46 million$56.10 millionViewN/AView Earnings Details
3/6/2018Q4 2017($0.14)$0.03$78.59 million$78.00 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.66)($0.67)$48.25 million$41.85 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.89)($0.44)$28.78 million$47.96 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.88)($0.85)$27.93 million$26.50 millionViewListenView Earnings Details
3/16/201712/31/2016($1.07)($0.78)$24.69 million$25.20 millionViewN/AView Earnings Details
11/2/2016Q316($1.22)($1.03)$19.76 million$23.00 millionViewN/AView Earnings Details
8/4/2016Q216($1.27)($1.14)$15.24 million$15.40 millionViewN/AView Earnings Details
5/5/2016Q116($1.26)($1.22)$13.74 million$18.90 millionViewN/AView Earnings Details
2/29/2016Q415($1.25)($1.50)$13.04 million$12.70 millionViewListenView Earnings Details
11/9/2015Q315($1.15)($1.27)$9.88 million$9.78 millionViewListenView Earnings Details
7/30/2015Q215($1.20)($1.14)$7.73 million$6.77 millionViewListenView Earnings Details
5/4/2015Q115($1.20)($1.15)$2.97 million$7.50 millionViewN/AView Earnings Details
2/27/2015Q414($0.83)($0.84)$7.99 million$12.70 millionViewListenView Earnings Details
11/6/2014Q314($0.90)($0.93)$1.76 million$1.69 millionViewN/AView Earnings Details
8/7/2014Q214($0.75)($0.86)$1.71 million$1.70 millionViewN/AView Earnings Details
5/6/2014($0.46)($0.58)$10.93 million$9.22 millionViewN/AView Earnings Details
3/6/2014Q413($0.57)($0.75)$6.15 million$4.40 millionViewN/AView Earnings Details
11/14/2013Q3($0.29)($0.19)$7.20 million$16.29 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.71)($5.51)$6.33 million$6.85 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

PTC Therapeutics (NASDAQ:PTCT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

PTC Therapeutics (NASDAQ PTCT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 83.52%
Insider Trading History for PTC Therapeutics (NASDAQ:PTCT)
Insider Trading History for PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics (NASDAQ PTCT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/5/2018Stuart Walter PeltzCEOSell2,230$18.03$40,206.9026,646View SEC Filing  
1/4/2018Christine Marie UtterInsiderSell412$17.67$7,280.04View SEC Filing  
1/4/2018Neil Gregory AlmsteadEVPSell77$17.67$1,360.59View SEC Filing  
5/23/2017Dawn SvoronosDirectorBuy25,000$13.49$337,250.0025,000View SEC Filing  
1/5/2017Neil Gregory AlmsteadEVPSell78$11.82$921.96View SEC Filing  
3/3/2016Mark RotheraInsiderBuy2,000$6.23$12,460.005,125View SEC Filing  
7/6/2015David P SouthwellDirectorSell23,604$47.52$1,121,662.08View SEC Filing  
6/18/2015Allan Steven JacobsonDirectorSell5,000$50.13$250,650.00View SEC Filing  
6/9/2015Stuart Walter PeltzCEOSell100,000$54.49$5,449,000.00View SEC Filing  
6/8/2015Mark Elliott BouldingVPSell56,849$55.04$3,128,968.96View SEC Filing  
6/8/2015Richard AldrichDirectorSell7,000$55.66$389,620.00View SEC Filing  
6/8/2015Stuart Walter PeltzCEOSell73,700$54.91$4,046,867.00View SEC Filing  
5/22/2015Shane William Charles KovacsCFOSell82,491$55.41$4,570,826.31View SEC Filing  
4/15/2015Neil Gregory AlmsteadEVPSell9,511$68.65$652,930.15View SEC Filing  
3/23/2015David P SouthwellDirectorSell2,317$69.04$159,965.68View SEC Filing  
3/23/2015Stuart Walter PeltzCEOSell47,200$69.14$3,263,408.00View SEC Filing  
3/20/2015Mark Elliott BouldingVPSell21,142$68.12$1,440,193.04View SEC Filing  
3/18/2015Allan Steven JacobsonDirectorSell16,616$76.00$1,262,816.00View SEC Filing  
3/17/2015Mark RotheraInsiderSell10,700$76.64$820,048.00View SEC Filing  
3/16/2015Michael L KrandaDirectorSell2,500$72.81$182,025.00View SEC Filing  
3/13/2015Robert J SpiegelInsiderSell1,030$75.10$77,353.00View SEC Filing  
3/10/2015Neil Gregory AlmsteadEVPSell79$70.71$5,586.09View SEC Filing  
3/9/2015Stuart Walter PeltzCEOSell47,201$70.74$3,338,998.74View SEC Filing  
2/25/2015Mark RotheraInsiderSell35,000$68.01$2,380,350.00View SEC Filing  
2/24/2015Mark RotheraInsiderSell1,000$67.70$67,700.00View SEC Filing  
2/23/2015Mark RotheraInsiderSell23,000$65.40$1,504,200.00View SEC Filing  
1/21/2015Neil Gregory AlmsteadEVPSell26,096$60.26$1,572,544.96View SEC Filing  
1/20/2015Mark RotheraInsiderSell3,000$60.02$180,060.00View SEC Filing  
1/16/2015Mark RotheraInsiderSell2,300$58.67$134,941.00View SEC Filing  
1/15/2015Claudia De Oliveira Ri HirawatPresidentSell2,149$57.19$122,901.31View SEC Filing  
1/14/2015Mark RotheraInsiderSell9,700$58.04$562,988.00View SEC Filing  
12/15/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$55.24$120,036.52View SEC Filing  
11/17/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$39.78$86,441.94View SEC Filing  
10/15/2014Claudia De Oliveira Ri HirawatPresidentSell45,661$36.15$1,650,645.15View SEC Filing  
10/10/2014Claudia De Oliveira Ri HirawatPresidentSell43,489$36.18$1,573,432.02View SEC Filing  
10/1/2014Stuart Walter PeltzCEOSell41,501$42.65$1,770,017.65View SEC Filing  
9/26/2014Mark RotheraInsiderSell16,000$44.63$714,080.00View SEC Filing  
9/18/2014Allan Steven JacobsonDirectorSell2,000$40.16$80,320.00View SEC Filing  
9/15/2014Mark RotheraInsiderSell8,000$36.24$289,920.00View SEC Filing  
5/22/2014Shane William Charles KovacsCFOSell1,650$14.74$24,321.0012,350View SEC Filing  
3/24/2014Stuart Walter PeltzCEOSell25,487$29.86$761,041.82135,902View SEC Filing  
3/21/2014Claudia De Oliveira Ri HirawatPresidentSell15,320$29.61$453,625.2034,737View SEC Filing  
3/21/2014David SouthwellDirectorSell2,317$30.93$71,664.8110,921View SEC Filing  
3/20/2014Mark Elliott BouldingVPSell10,049$30.96$311,117.0432,235View SEC Filing  
3/19/2014Neil Gregory AlmsteadVPSell10,859$31.91$346,510.6929,881View SEC Filing  
3/18/2014Allan Steven JacobsonDirectorSell7,616$31.18$237,466.8830,464View SEC Filing  
3/14/2014Michael KrandaDirectorSell1,186$31.02$36,789.724,742View SEC Filing  
3/13/2014Robert SpiegelInsiderSell1,186$31.75$37,655.504,269View SEC Filing  
3/7/2014Stuart Walter PeltzCEOSell27,414$29.91$819,952.74161,389View SEC Filing  
12/17/2013Hbm Healthcare Investments (Camajor shareholderSell66,667$19.08$1,272,006.362,441,504View SEC Filing  
6/25/2013Adam KoppelDirectorBuy1,250,000$15.00$18,750,000.00View SEC Filing  
6/25/2013Hbm Healthcare Investments (CaMajor ShareholderBuy666,676$15.00$10,000,140.00View SEC Filing  
6/25/2013Mark RotheraInsiderBuy25,000$15.00$375,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

PTC Therapeutics (NASDAQ PTCT) News Headlines

Source:
DateHeadline
Notice to Current PTC Stockholders: Rosen Law Firm Announces Preliminary Approval of Derivative Settlement on Behalf of PTC Therapeutics, Inc.Notice to Current PTC Stockholders: Rosen Law Firm Announces Preliminary Approval of Derivative Settlement on Behalf of PTC Therapeutics, Inc.
finance.yahoo.com - May 18 at 5:36 PM
PTC Therapeutics (PTCT) Upgraded to Buy by ValuEnginePTC Therapeutics (PTCT) Upgraded to Buy by ValuEngine
www.americanbankingnews.com - May 17 at 10:23 PM
Q2 2018 EPS Estimates for PTC Therapeutics Increased by Analyst (PTCT)Q2 2018 EPS Estimates for PTC Therapeutics Increased by Analyst (PTCT)
www.americanbankingnews.com - May 14 at 1:56 AM
PTC Therapeutics (PTCT) Downgraded to Hold at ValuEnginePTC Therapeutics (PTCT) Downgraded to Hold at ValuEngine
www.americanbankingnews.com - May 11 at 9:23 PM
PTC Therapeutics (PTCT) Posts  Earnings Results, Misses Estimates By $0.03 EPSPTC Therapeutics (PTCT) Posts Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - May 10 at 8:29 PM
PTC Therapeutics (PTCT) Receives Average Recommendation of "Hold" from BrokeragesPTC Therapeutics (PTCT) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 10 at 7:45 PM
William Blair Reiterates "Hold" Rating for PTC Therapeutics (PTCT)William Blair Reiterates "Hold" Rating for PTC Therapeutics (PTCT)
www.americanbankingnews.com - May 10 at 1:02 PM
PTC Therapeutics (PTCT) CEO Stuart Peltz on Q1 2018 Results - Earnings Call TranscriptPTC Therapeutics' (PTCT) CEO Stuart Peltz on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 8:42 AM
Edited Transcript of PTCT earnings conference call or presentation 9-May-18 8:30pm GMTEdited Transcript of PTCT earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 8:42 AM
PTC Therapeutics Q1 revenues up 112%PTC Therapeutics Q1 revenues up 112%
seekingalpha.com - May 9 at 5:17 PM
PTC Therapeutics misses by $0.03, misses on revenuePTC Therapeutics misses by $0.03, misses on revenue
seekingalpha.com - May 9 at 5:17 PM
PTC Therapeutics: 1Q Earnings SnapshotPTC Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 5:17 PM
PTC Therapeutics Reports First Quarter 2018 Financial Results and Provides a Corporate UpdatePTC Therapeutics Reports First Quarter 2018 Financial Results and Provides a Corporate Update
finance.yahoo.com - May 9 at 5:17 PM
PTC Therapeutics (PTCT) Lowered to Hold at Zacks Investment ResearchPTC Therapeutics (PTCT) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 5:12 PM
Analysis: Positioning to Benefit within Entergy, Schneider National, C.H. Robinson Worldwide, PTC Therapeutics, Guess?, and Immunomedics — Research Highlights Growth, Revenue, and Consolidated ResultsAnalysis: Positioning to Benefit within Entergy, Schneider National, C.H. Robinson Worldwide, PTC Therapeutics, Guess?, and Immunomedics — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - May 9 at 8:38 AM
PTC Therapeutics (PTCT) Upgraded to Hold at ValuEnginePTC Therapeutics (PTCT) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 7:06 PM
PTC Therapeutics Target of Unusually Large Options Trading (PTCT)PTC Therapeutics Target of Unusually Large Options Trading (PTCT)
www.americanbankingnews.com - May 2 at 6:58 AM
Atara Biotherapeutics Expands Commercial Leadership Team with the Appointment of Manuela Maronati as General ...Atara Biotherapeutics Expands Commercial Leadership Team with the Appointment of Manuela Maronati as General ...
globenewswire.com - May 1 at 8:41 AM
PTC Therapeutics to Participate at Upcoming Investor ConferencePTC Therapeutics to Participate at Upcoming Investor Conference
finance.yahoo.com - April 30 at 8:40 AM
PTC Therapeutics (PTCT) Scheduled to Post Quarterly Earnings on MondayPTC Therapeutics (PTCT) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 8:34 AM
PTC Therapeutics (PTCT) Short Interest UpdatePTC Therapeutics (PTCT) Short Interest Update
www.americanbankingnews.com - April 28 at 2:54 AM
June 8th Options Now Available For PTC Therapeutics (PTCT)June 8th Options Now Available For PTC Therapeutics (PTCT)
www.nasdaq.com - April 26 at 5:05 PM
PTC Therapeutics (PTCT) Stock Rating Upgraded by Zacks Investment ResearchPTC Therapeutics (PTCT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 19 at 3:34 PM
PTC Therapeutics (PTCT) Forecasted to Post Q1 2018 Earnings of ($0.61) Per SharePTC Therapeutics (PTCT) Forecasted to Post Q1 2018 Earnings of ($0.61) Per Share
www.americanbankingnews.com - April 18 at 7:42 AM
PTC Therapeutics (PTCT) Receives Consensus Rating of "Hold" from AnalystsPTC Therapeutics (PTCT) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 15 at 7:31 PM
Free Research Reports on These Biotech Stocks -- Prothena, PTC Therapeutics, Pulmatrix, and Puma BiotechFree Research Reports on These Biotech Stocks -- Prothena, PTC Therapeutics, Pulmatrix, and Puma Biotech
www.prnewswire.com - April 13 at 7:22 AM
PTC Therapeutics Announces Full Exercise of Underwriters Option to Purchase Additional SharesPTC Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - April 12 at 5:19 PM
PTC Therapeutics (PTCT) Downgraded by JPMorgan ChasePTC Therapeutics (PTCT) Downgraded by JPMorgan Chase
www.americanbankingnews.com - April 7 at 8:50 PM
PTC Therapeutics (PTCT) Downgraded by Bank of AmericaPTC Therapeutics (PTCT) Downgraded by Bank of America
www.americanbankingnews.com - April 4 at 8:34 PM
PTC Therapeutics and CHDI Foundation Announce a Collaboration on a Small-Molecule Therapeutic for Huntingtons DiseasePTC Therapeutics and CHDI Foundation Announce a Collaboration on a Small-Molecule Therapeutic for Huntington's Disease
finance.yahoo.com - April 4 at 8:39 AM
PTC Therapeutics (PTCT) Upgraded to "Hold" by Zacks Investment ResearchPTC Therapeutics (PTCT) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 3 at 9:18 PM
Barclays Lowers PTC Therapeutics (PTCT) to UnderweightBarclays Lowers PTC Therapeutics (PTCT) to Underweight
www.americanbankingnews.com - April 3 at 5:16 PM
PTC Therapeutics (PTCT) Upgraded by ValuEngine to "Sell"PTC Therapeutics (PTCT) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - March 30 at 1:18 PM
PTC Therapeutics Sees Unusually High Options Volume (PTCT)PTC Therapeutics Sees Unusually High Options Volume (PTCT)
www.americanbankingnews.com - March 30 at 7:06 AM
PTC Therapeutics Announces Proposed Public Offering of Common StockPTC Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 27 at 5:01 PM
Credit Suisse Group Reiterates Buy Rating for PTC Therapeutics (PTCT)Credit Suisse Group Reiterates Buy Rating for PTC Therapeutics (PTCT)
www.americanbankingnews.com - March 26 at 4:18 PM
PTC Therapeutics, Inc. (PTCT) Receives Consensus Recommendation of "Hold" from AnalystsPTC Therapeutics, Inc. (PTCT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 21 at 7:36 PM
FIREFISH Transitions into Pivotal Phase - PR Newswire - PR Newswire (press release)FIREFISH Transitions into Pivotal Phase - PR Newswire - PR Newswire (press release)
www.prnewswire.com - March 16 at 8:40 AM
FIREFISH Transitions into Pivotal PhaseFIREFISH Transitions into Pivotal Phase
finance.yahoo.com - March 15 at 8:34 AM
PTC Therapeutics (PTCT) Rating Increased to Buy at Zacks Investment ResearchPTC Therapeutics (PTCT) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 10 at 6:06 AM
Q1 2018 EPS Estimates for PTC Therapeutics, Inc. (PTCT) Lowered by William BlairQ1 2018 EPS Estimates for PTC Therapeutics, Inc. (PTCT) Lowered by William Blair
www.americanbankingnews.com - March 9 at 7:26 AM
PTC Therapeutics, Inc. Forecasted to Earn Q1 2019 Earnings of ($0.38) Per Share (PTCT)PTC Therapeutics, Inc. Forecasted to Earn Q1 2019 Earnings of ($0.38) Per Share (PTCT)
www.americanbankingnews.com - March 8 at 11:50 AM
PTC Therapeutics (PTCT) Price Target Raised to $24.00PTC Therapeutics (PTCT) Price Target Raised to $24.00
www.americanbankingnews.com - March 7 at 4:15 PM
PTC Therapeutics (PTCT) Receives Hold Rating from William BlairPTC Therapeutics (PTCT) Receives Hold Rating from William Blair
www.americanbankingnews.com - March 7 at 12:45 PM
PTC Therapeutics Q4 Earnings Preview - BenzingaPTC Therapeutics Q4 Earnings Preview - Benzinga
www.benzinga.com - March 7 at 8:41 AM
Investor Expectations to Drive Momentum within AVEO Pharmaceuticals, PTC Therapeutics, NGL Energy Partners LP, Bemis, CorMedix, and Patterson Companies — Discovering Underlying Factors of InfluenceInvestor Expectations to Drive Momentum within AVEO Pharmaceuticals, PTC Therapeutics, NGL Energy Partners LP, Bemis, CorMedix, and Patterson Companies — Discovering Underlying Factors of Influence
finance.yahoo.com - March 7 at 8:41 AM
PTC Therapeutics (PTCT) Issues Quarterly  Earnings Results, Beats Expectations By $0.25 EPSPTC Therapeutics (PTCT) Issues Quarterly Earnings Results, Beats Expectations By $0.25 EPS
www.americanbankingnews.com - March 6 at 9:12 PM
PTC Therapeutics, Inc. to Host Earnings CallPTC Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 6 at 5:27 PM
PTC Therapeutics Q4 Earnings PreviewPTC Therapeutics Q4 Earnings Preview
finance.yahoo.com - March 6 at 5:27 PM
PTC Therapeutics posts 4Q profitPTC Therapeutics posts 4Q profit
finance.yahoo.com - March 6 at 5:27 PM

SEC Filings

PTC Therapeutics (NASDAQ:PTCT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

PTC Therapeutics (NASDAQ:PTCT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

PTC Therapeutics (NASDAQ PTCT) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.